Top

Published in:

01-06-2013 | Educational Review

Cardiovascular risk assessment in children with chronic kidney disease

Authors: Rukshana Shroff, Arianna Dégi, Andrea Kerti, Éva Kis, Orsolya Cseprekál, Kálmán Tory, Attila J. Szabó, George S. Reusz

Published in: Pediatric Nephrology | Issue 6/2013

Abstract

Chronic kidney disease (CKD) is a major factor contributing to cardiovascular (CV) morbidity and mortality with the highest risk in patients on dialysis. An estimation of CV risk is important not only to identify potential modifiable risk factors but also to evaluate the effect of treatments aimed to reduce the risk. Non-invasive methods of measuring vascular changes and circulating biomarkers are available to assess the presence and severity of cardiovascular damage. These include measures of structural (carotid intima-media thickness and coronary artery calcification score) and functional (aortic pulse wave velocity, 24-h ambulatory blood pressure monitoring, ambulatory arterial stiffness index, heart rate variability and flow-mediated dilatation) changes in the vessel wall. In addition, a number of circulating biomarkers of vascular damage and its progression have been studied. Many of these tests are well validated as surrogate markers of future cardiovascular events and death in adult CKD patients, but need technical adaptation, standardization and validation for use in children. With our current state of knowledge, these are best reserved for research studies and scarce clinical resources may be better utilized for preventative strategies to reduce the modifiable risk factors for calcification from early CKD stages.

Available only for authorised users

Shroff R, Quinlan C, Mitsnefes M (2011) Uraemic vasculopathy in children with chronic kidney disease: prevention or damage limitation? Pediatr Nephrol 26:853–865PubMedCrossRef

Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY (2004) Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351:1296–1305PubMedCrossRef

Parfrey PS, Foley RN (1999) The clinical epidemiology of cardiac disease in chronic renal failure. J Am Soc Nephrol: JASN 10:1606–1615PubMed

Parekh RS, Carroll CE, Wolfe RA, Port FK (2002) Cardiovascular mortality in children and young adults with end-stage kidney disease. J Pediatr 141:191–197PubMedCrossRef

McDonald SP, Craig JC (2004) Long-term survival of children with end-stage renal disease. N Engl J Med 350:2654–2662PubMedCrossRef

Oh J, Wunsch R, Turzer M, Bahner M, Raggi P, Querfeld U, Mehls O, Schaefer F (2002) Advanced coronary and carotid arteriopathy in young adults with childhood-onset chronic renal failure. Circulation 106:100–105PubMedCrossRef

Covic A, Gusbeth-Tatomir P, Goldsmith DJ (2003) The challenge of cardiovascular risk factors in end-stage renal disease. J Nephrol 16:476–486PubMed

Urbina EM, Williams RV, Alpert BS, Collins RT, Daniels SR, Hayman L, Jacobson M, Mahoney L, Mietus-Snyder M, Rocchini A, Steinberger J, McCrindle B (2009) Noninvasive assessment of subclinical atherosclerosis in children and adolescents: recommendations for standard assessment for clinical research: a scientific statement from the American Heart Association. Hypertension 54:919–950PubMedCrossRef

Ichida F, Aubert A, Denef B, Dumoulin M, Van der Hauwaert LG (1987) Cross-sectional echocardiographic assessment of great artery diameters in infants and children. Br Hear J 58:627–634CrossRef

10.

van Meurs-van Woezik H, Klein HW, Markus-Silvis L, Krediet P (1983) Comparison of the growth of the tunica media of the ascending aorta, aortic isthmus and descending aorta in infants and children. J Anat 136:273–281PubMed

11.

Jourdan C, Wuhl E, Litwin M, Fahr K, Trelewicz J, Jobs K, Schenk JP, Grenda R, Mehls O, Troger J, Schaefer F (2005) Normative values for intima-media thickness and distensibility of large arteries in healthy adolescents. J Hypertens 23:1707–1715PubMedCrossRef

12.

Laurent S, Cockcroft J, Van Bortel L, Boutouyrie P, Giannattasio C, Hayoz D, Pannier B, Vlachopoulos C, Wilkinson I, Struijker-Boudier H (2006) Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Hear J 27:2588–2605CrossRef

13.

Pannier B, Guerin AP, Marchais SJ, Safar ME, London GM (2005) Stiffness of capacitive and conduit arteries: prognostic significance for end-stage renal disease patients. Hypertension 45:592–596PubMedCrossRef

14.

(2010) Determinants of pulse wave velocity in healthy people and in the presence of cardiovascular risk factors: ‘establishing normal and reference values’. Eur Heart J 31:2338–2350

15.

Kis E, Cseprekal O, Kerti A, Salvi P, Benetos A, Tisler A, Szabo A, Tulassay T, Reusz GS (2011) Measurement of pulse wave velocity in children and young adults: a comparative study using three different devices. Hypertens Res 34:1197–1202PubMedCrossRef

16.

Kracht D, Shroff R, Baig S, Doyon A, Jacobi C, Zeller R, Querfeld U, Schaefer F, Wuhl E, Schmidt BM, Melk A (2011) Validating a new oscillometric device for aortic pulse wave velocity measurements in children and adolescents. Am J Hypertens 24:1294–1299PubMedCrossRef

17.

Cseprekal O, Kis E, Schaffer P, Othmane Tel H, Fekete BC, Vannay A, Szabo AJ, Remport A, Szabo A, Tulassay T, Reusz GS (2009) Pulse wave velocity in children following renal transplantation. Nephrol Dial Transplant 24:309–315PubMedCrossRef

18.

Kis E, Cseprekal O, Horvath Z, Katona G, Fekete BC, Hrapka E, Szabo A, Szabo AJ, Fekete A, Reusz GS (2008) Pulse wave velocity in end-stage renal disease: influence of age and body dimensions. Pediatr Res 63:95–98PubMedCrossRef

19.

Reusz GS, Cseprekal O, Temmar M, Kis E, Cherif AB, Thaleb A, Fekete A, Szabo AJ, Benetos A, Salvi P (2010) Reference values of pulse wave velocity in healthy children and teenagers. Hypertension 56:217–224PubMedCrossRef

20.

Covic A, Mardare N, Gusbeth-Tatomir P, Brumaru O, Gavrilovici C, Munteanu M, Prisada O, Goldsmith DJ (2006) Increased arterial stiffness in children on haemodialysis. Nephrol Dial Transplant 21:729–735PubMedCrossRef

21.

Kis E, Cseprekal O, Biro E, Kelen K, Ferenczi D, Kerti A, Szabo AJ, Szabo A, Reusz GS (2009) Effects of bone and mineral metabolism on arterial elasticity in chronic renal failure. Pediatric Nephrol 24:2413–2420CrossRef

22.

Shroff RC, Donald AE, Hiorns MP, Watson A, Feather S, Milford D, Ellins EA, Storry C, Ridout D, Deanfield J, Rees L (2007) Mineral metabolism and vascular damage in children on dialysis. J Am Soc Nephrol 18:2996–3003PubMedCrossRef

23.

Litwin M, Niemirska A (2009) Intima-media thickness measurements in children with cardiovascular risk factors. Pediatric Nephrol 24:707–719CrossRef

24.

Benedetto FA, Mallamaci F, Tripepi G, Zoccali C (2001) Prognostic value of ultrasonographic measurement of carotid intima media thickness in dialysis patients. J Am Soc Nephrol 12:2458–2464PubMed

25.

Mitsnefes MM, Kimball TR, Kartal J, Witt SA, Glascock BJ, Khoury PR, Daniels SR (2005) Cardiac and vascular adaptation in pediatric patients with chronic kidney disease: role of calcium-phosphorus metabolism. J Am Soc Nephrol 16:2796–2803PubMedCrossRef

26.

Litwin M, Wuhl E, Jourdan C, Trelewicz J, Niemirska A, Fahr K, Jobs K, Grenda R, Wawer ZT, Rajszys P, Troger J, Mehls O, Schaefer F (2005) Altered morphologic properties of large arteries in children with chronic renal failure and after renal transplantation. J Am Soc Nephrol 16:1494–1500PubMedCrossRef

27.

Shroff R, Egerton M, Bridel M, Shah V, Donald AE, Cole TJ, Hiorns MP, Deanfield JE, Rees L (2008) A bimodal association of vitamin D levels and vascular disease in children on dialysis. J Am Soc Nephrol 19:1239–1246PubMedCrossRef

28.

Haussler MR, Whitfield GK, Haussler CA, Hsieh JC, Thompson PD, Selznick SH, Dominguez CE, Jurutka PW (1998) The nuclear vitamin D receptor: biological and molecular regulatory properties revealed. J Bone Miner Res 13:325–349PubMedCrossRef

29.

Patel S, Farragher T, Berry J, Bunn D, Silman A, Symmons D (2007) Association between serum vitamin D metabolite levels and disease activity in patients with early inflammatory polyarthritis. Arthritis Rheum 56:2143–2149PubMedCrossRef

30.

Levin A, Li YC (2005) Vitamin D and its analogues: do they protect against cardiovascular disease in patients with kidney disease? Kidney Int 68:1973–1981PubMedCrossRef

31.

Schleithoff SS, Zittermann A, Tenderich G, Berthold HK, Stehle P, Koerfer R (2006) Vitamin D supplementation improves cytokine profiles in patients with congestive heart failure: a double-blind, randomized, placebo-controlled trial. Am J Clin Nutr 83:754–759PubMed

32.

Muller K, Haahr PM, Diamant M, Rieneck K, Kharazmi A, Bendtzen K (1992) 1,25-Dihydroxyvitamin D3 inhibits cytokine production by human blood monocytes at the post-transcriptional level. Cytokine 4:506–512PubMedCrossRef

33.

Holick MF (2007) Vitamin D deficiency. N Engl J Med 357:266–281PubMedCrossRef

34.

Shroff R, Knott C, Rees L (2010) The virtues of vitamin D–but how much is too much? Pediatr Nephrol 25:1607–1620PubMedCrossRef

35.

Wuhl E, Witte K, Soergel M, Mehls O, Schaefer F (2002) Distribution of 24-h ambulatory blood pressure in children: normalized reference values and role of body dimensions. J Hypertens 20:1995–2007PubMedCrossRef

36.

Hadtstein C, Wuhl E, Soergel M, Witte K, Schaefer F (2004) Normative values for circadian and ultradian cardiovascular rhythms in childhood. Hypertension 43:547–554PubMedCrossRef

37.

Wuhl E, Hadtstein C, Mehls O, Schaefer F (2005) Ultradian but not circadian blood pressure rhythms correlate with renal dysfunction in children with chronic renal failure. J Am Soc Nephrol 16:746–754PubMedCrossRef

38.

Dolan E, Thijs L, Li Y, Atkins N, McCormack P, McClory S, O’Brien E, Staessen JA, Stanton AV (2006) Ambulatory arterial stiffness index as a predictor of cardiovascular mortality in the Dublin Outcome Study. Hypertension 47:365–370PubMedCrossRef

39.

Li Y, Wang JG, Dolan E, Gao PJ, Guo HF, Nawrot T, Stanton AV, Zhu DL, O’Brien E, Staessen JA (2006) Ambulatory arterial stiffness index derived from 24-hour ambulatory blood pressure monitoring. Hypertension 47:359–364PubMedCrossRef

40.

Simonetti GD, von Vigier RO, Wuhl E, Mohaupt MG (2008) Ambulatory arterial stiffness index is increased in hypertensive childhood disease. Pediatr Res 64:303–307PubMedCrossRef

41.

Stergiou GS, Kollias A, Giovas PP, Papagiannis J, Roussias LG (2010) Ambulatory arterial stiffness index, pulse pressure and pulse wave velocity in children and adolescents. Hypertens Res: Official Journal of the Japanese Society of Hypertension 33:1272–1277CrossRef

42.

Shimbo D, Grahame-Clarke C, Miyake Y, Rodriguez C, Sciacca R, Di Tullio M, Boden-Albala B, Sacco R, Homma S (2007) The association between endothelial dysfunction and cardiovascular outcomes in a population-based multi-ethnic cohort. Atherosclerosis 192:197–203PubMedCrossRef

43.

Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Charbonneau F, Creager MA, Deanfield J, Drexler H, Gerhard-Herman M, Herrington D, Vallance P, Vita J, Vogel R (2002) Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 39:257–265PubMedCrossRef

44.

Moens AL, Goovaerts I, Claeys MJ, Vrints CJ (2005) Flow-mediated vasodilation: a diagnostic instrument, or an experimental tool? Chest 127:2254–2263PubMedCrossRef

45.

Yilmaz MI, Stenvinkel P, Sonmez A, Saglam M, Yaman H, Kilic S, Eyileten T, Caglar K, Oguz Y, Vural A, Cakar M, Altun B, Yenicesu M, Carrero JJ (2011) Vascular health, systemic inflammation and progressive reduction in kidney function; clinical determinants and impact on cardiovascular outcomes. Nephrol Dial Transplant 26:3537–3543PubMedCrossRef

46.

Hussein G, Bughdady Y, Kandil ME, Bazaraa HM, Taher H (2008) Doppler assessment of brachial artery flow as a measure of endothelial dysfunction in pediatric chronic renal failure. Pediatric Nephrol 23:2025–2030CrossRef

47.

Bots ML, Westerink J, Rabelink TJ, de Koning EJ (2005) Assessment of flow-mediated vasodilatation (FMD) of the brachial artery: effects of technical aspects of the FMD measurement on the FMD response. Eur Hear J 26:363–368CrossRef

48.

Ranpuria R, Hall M, Chan CT, Unruh M (2008) Heart rate variability (HRV) in kidney failure: measurement and consequences of reduced HRV. Nephrol Dial Transplant 23:444–449PubMedCrossRef

49.

(1996) Heart rate variability: standards of measurement, physiological interpretation and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Circulation 93:1043–1065

50.

Tory K, Suveges Z, Horvath E, Bokor E, Sallay P, Berta K, Szabo A, Tulassay T, Reusz GS (2003) Autonomic dysfunction in uremia assessed by heart rate variability. Pediatr Nephrol 18:1167–1171PubMedCrossRef

51.

Tory K, Horvath E, Suveges Z, Fekete A, Sallay P, Berta K, Szabo T, Szabo AJ, Tulassay T, Reusz GS (2004) Effect of propranolol on heart rate variability in patients with end-stage renal disease: a double-blind, placebo-controlled, randomized crossover pilot trial. Clin Nephrol 61:316–323PubMed

52.

Ewing DJ, Winney R (1975) Autonomic function in patients with chronic renal failure on intermittent haemodialysis. Nephron 15:424–429PubMedCrossRef

53.

Bar-Haim Y, Marshall PJ, Fox NA (2000) Developmental changes in heart period and high-frequency heart period variability from 4 months to 4 years of age. Dev Psychobiol 37:44–56PubMedCrossRef

54.

Massin M, von Bernuth G (1997) Normal ranges of heart rate variability during infancy and childhood. Pediatr Cardiol 18:297–302PubMedCrossRef

55.

Civilibal M, Caliskan S, Oflaz H, Sever L, Candan C, Canpolat N, Kasapcopur O, Bugra Z, Arisoy N (2007) Traditional and “new” cardiovascular risk markers and factors in pediatric dialysis patients. Pediatric Nephrol 22:1021–1029CrossRef

56.

Srivaths PR, Silverstein DM, Leung J, Krishnamurthy R, Goldstein SL (2010) Malnutrition-inflammation-coronary calcification in pediatric patients receiving chronic hemodialysis. Hemodial Int: International Symposium on Home Hemodialysis 14:263–269CrossRef

57.

Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, Wang Y, Chung J, Emerick A, Greaser L, Elashoff RM, Salusky IB (2000) Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 342:1478–1483PubMedCrossRef

58.

Schoppet M, Shroff RC, Hofbauer LC, Shanahan CM (2008) Exploring the biology of vascular calcification in chronic kidney disease: what’s circulating? Kidney Int 73:384–390PubMedCrossRef

59.

Ketteler M, Bongartz P, Westenfeld R, Wildberger JE, Mahnken AH, Bohm R, Metzger T, Wanner C, Jahnen-Dechent W, Floege J (2003) Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study. Lancet 361:827–833PubMedCrossRef

60.

Shroff RC, McNair R, Figg N, Skepper JN, Schurgers L, Gupta A, Hiorns M, Donald AE, Deanfield J, Rees L, Shanahan CM (2008) Dialysis accelerates medial vascular calcification in part by triggering smooth muscle cell apoptosis. Circulation 118:1748–1757PubMedCrossRef

61.

Hermans MM, Brandenburg V, Ketteler M, Kooman JP, van der Sande FM, Boeschoten EW, Leunissen KM, Krediet RT, Dekker FW (2007) Association of serum fetuin-A levels with mortality in dialysis patients. Kidney Int 72:202–207PubMedCrossRef

62.

Shroff RC, Shah V, Hiorns MP, Schoppet M, Hofbauer LC, Hawa G, Schurgers LJ, Singhal A, Merryweather I, Brogan P, Shanahan C, Deanfield J, Rees L (2008) The circulating calcification inhibitors, fetuin-A and osteoprotegerin, but not matrix Gla protein, are associated with vascular stiffness and calcification in children on dialysis. Nephrol Dial Transplant 23:3263–3271PubMedCrossRef

63.

Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Sander S, Van G, Tarpley J, Derby P, Lee R, Boyle WJ (1997) Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89:309–319PubMedCrossRef

64.

Hjelmesaeth J, Ueland T, Flyvbjerg A, Bollerslev J, Leivestad T, Jenssen T, Hansen TK, Thiel S, Sagedal S, Roislien J, Hartmann A (2006) Early posttransplant serum osteoprotegerin levels predict long-term (8-year) patient survival and cardiovascular death in renal transplant patients. J Am Soc Nephrol 17:1746–1754PubMedCrossRef

65.

Braam LA, Dissel P, Gijsbers BL, Spronk HM, Hamulyak K, Soute BA, Debie W, Vermeer C (2000) Assay for human matrix gla protein in serum: potential applications in the cardiovascular field. Arterioscler Thromb Vasc Biol 20:1257–1261PubMedCrossRef

66.

Jono S, Ikari Y, Vermeer C, Dissel P, Hasegawa K, Shioi A, Taniwaki H, Kizu A, Nishizawa Y, Saito S (2004) Matrix Gla protein is associated with coronary artery calcification as assessed by electron-beam computed tomography. Thromb Haemost 91:790–794PubMed

67.

Shroff R, Wan M, Rees L (2011) Can vitamin D slow down the progression of chronic kidney disease? Pediatr Nephrol

68.

Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus JM, Thadhani R (2003) Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 349:446–456PubMedCrossRef

69.

Tentori F, Hunt WC, Stidley CA, Rohrscheib MR, Bedrick EJ, Meyer KB, Johnson HK, Zager PG (2006) Mortality risk among hemodialysis patients receiving different vitamin D analogs. Kidney Int 70:1858–1865PubMedCrossRef

70.

Gutierrez OM, Januzzi JL, Isakova T, Laliberte K, Smith K, Collerone G, Sarwar A, Hoffmann U, Coglianese E, Christenson R, Wang TJ, deFilippi C, Wolf M (2009) Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation 119:2545–2552PubMedCrossRef

71.

Gutierrez OM, Mannstadt M, Isakova T, Rauh-Hain JA, Tamez H, Shah A, Smith K, Lee H, Thadhani R, Juppner H, Wolf M (2008) Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 359:584–592PubMedCrossRef

72.

van Husen M, Fischer AK, Lehnhardt A, Klaassen I, Moller K, Muller-Wiefel DE, Kemper MJ (2010) Fibroblast growth factor 23 and bone metabolism in children with chronic kidney disease. Kidney Int 78:200–206PubMedCrossRef

73.

Wesseling-Perry K, Pereira RC, Wang H, Elashoff RM, Sahney S, Gales B, Juppner H, Salusky IB (2009) Relationship between plasma fibroblast growth factor-23 concentration and bone mineralization in children with renal failure on peritoneal dialysis. J Clin Endocrinol Metab 94:511–517PubMedCrossRef

74.

Erbel R, Mohlenkamp S, Kerkhoff G, Budde T, Schmermund A (2007) Non-invasive screening for coronary artery disease: calcium scoring. Heart 93:1620–1629PubMedCrossRef

75.

Agatston AS, Janowitz WR, Hildner FJ, Zusmer NR, Viamonte M Jr, Detrano R (1990) Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol 15:827–832PubMedCrossRef

Title: Cardiovascular risk assessment in children with chronic kidney disease
Authors: Rukshana Shroff
Arianna Dégi
Andrea Kerti
Éva Kis
Orsolya Cseprekál
Kálmán Tory
Attila J. Szabó
George S. Reusz
Publication date: 01-06-2013
Publisher: Springer-Verlag
Published in: Pediatric Nephrology / Issue 6/2013
Print ISSN: 0931-041X
Electronic ISSN: 1432-198X
DOI: https://doi.org/10.1007/s00467-012-2325-3

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Cardiovascular risk assessment in children with chronic kidney disease

Abstract

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2013

Hydronephrosis associated with ureteral wall thickness: Question

Difficulties in diagnosing severe Pneumocystis jiroveci pneumonia after rituximab therapy for steroid-dependent nephrotic syndrome

Preoperative plasma FGF23 levels predict acute kidney injury in children: results of a pilot study

The quality of cardiovascular disease care for adolescents with kidney disease: a Midwest Pediatric Nephrology Consortium study

L-FABP can be an early marker of acute kidney injury in children

Cure of relapsing nephrosis by an allogeneic marrow graft for chronic myelogenous leukemia